Document is current
Any future updates will be listed below
-
Authors
Jiang, Xiangrui
Su, Haixia
Shang, Weijuan
Zhou, Feng https://orcid.org/0009-0007-3050-6239
Zhang, Yan
Zhao, Wenfeng
Zhang, Qiumeng
Xie, Hang
Jiang, Lei
Nie, Tianqing
Yang, Feipu
Xiong, Muya
Huang, Xiaoxing
Li, Minjun
Chen, Ping
Peng, Shaoping
Xiao, Gengfu https://orcid.org/0000-0001-9401-235X
Jiang, Hualiang https://orcid.org/0000-0003-0656-6315
Tang, Renhong
Zhang, Leike https://orcid.org/0000-0002-2593-2571
Shen, Jingshan https://orcid.org/0000-0001-9679-9934
Xu, Yechun https://orcid.org/0000-0002-1581-6155
-
Funding
Funding for this research was provided by:
Shanghai Science and Technology Development Foundation (No. 22YF1457300)
- License Information
-
More Information
Article History
Received: 18 April 2023
Accepted: 25 September 2023
First Online: 13 October 2023
Competing interests
: X.J., Y.X., L.Z., H.S., Q.Z., W.Z., W.S., J.S., G.X., and H.J. are co-inventors of the patent (CN202111168232.4, China) that cover 3CL<sup>pro</sup> inhibitors included in this study. F. Z., L.J., X.H., P.C., S.P., and R.T. are employers of Simcere Co. Ltd. F. Z., L.J., X.H., P.C., S.P., and R.T. are shareholders in Simcere Co. Ltd. All other authors declare no competing interests.
